medigraphic.com
Organo Oficial de la Sociedad Mexicana de Urología

2024, Number 1

Next >>

Rev Mex Urol 2024; 84 (1)

Biochemical alterations and paraneoplasic syndromes in patients with renal carcinoma

Cruz-García-Villa P, Badillo-Silva FM, Reyes-Acquart Á

Language: Spanish
References: 18
Page: 1-13
PDF size: 292.66 Kb.


ABSTRACT

Introduction: Renal carcinoma can show biochemical and paraneoplasic alterations at the moment of its diagnosis. Its diagnosis can be delayed due to these biochemical alterations. About 20 % of patients with renal carcinoma can have paraneoplasic syndromes or biochemical alterations.
Method: We reviewed the information of patients treated with nephrectomy for renal cell carcinoma between 2015 and 2022. We analyzed demographic, clinical and oncological variables. We performed a retrospective, descriptive, analytical study.
Results: We reviewed 65 files. Prevalence in males was higher with 72.3 %. Age mean was 66 years. Renal cell carcinoma was found in 70 % of patients. 34.4 % presented with anemia, LDH was elevated in 9.5 %. Hypercalcemia presented in 7.8 %. GGT was elevated in 21.4 %. Alcaline phosphatase was elevated in 29.2 %. 13 % showed hipoalbuminemia. Globular sedimentation rate was high in 75 %. Prothrombin time was high in 9.1 %. Neutrophil- lymphocyte ratio (NLR) was high in 33 %.
Conclusions: Renal carcinoma is a pathology that can show biochemical alterations and different paraneoplasic syndromes. Diagnosis and management must be individualized. Mexican population shows similar biochemical alterations compared to the data reported in international literature.


REFERENCES

  1. Linehan WM, Ricketts CJ. The Cancer GenomeAtlas of renal cell carcinoma: findings andclinical implications. Nature Reviews Urology. 2019;16(9): 539–552. https://doi.org/10.1038/s41585-019-0211-5.

  2. Kim HL, Belldegrun AS, Freitas DG, BuiMHT, Han KR, Dorey FJ, et al. ParaneoplasticSigns and Symptoms of Renal Cell Carcinoma:Implications for Prognosis. Journal of Urology.2003;170(5): 1742–1746. https://doi.org/10.1097/01.ju.0000092764.81308.6a.

  3. Palapattu GS, Kristo B, Rajfer J. ParaneoplasticSyndromes in Urologic Malignancy: The ManyFaces of Renal Cell Carcinoma. Reviews inUrology. 2002;4(4): 163–170.

  4. Muggia FM. Overview of cancer-relatedhypercalcemia: epidemiology and etiology.Seminars in Oncology. 1990;17(2 Suppl 5): 3–9.

  5. Mundy GR, Ibbotson KJ, D’Souza SM, SimpsonEL, Jacobs JW, Martin TJ. The Hypercalcemiaof Cancer: Clinical Implications and PathogenicMechanisms. Flier JS, Moore MJ (eds.) NewEngland Journal of Medicine. 1984;310(26):1718–1727. https://doi.org/10.1056/nejm198406283102607.

  6. Chasan SA, Pothel LR, Huben RE. Managementand prognostic significance hypercalcemiain renal cell carcinoma. Urology. 1989;33(3):167–170. https://doi.org/10.1016/0090-4295(89)90383-x.

  7. Dahl T, Eide I, Fryjordet A. Hypernephromaand Hypertension. Acta Medica Scandinavica.1981;209(1–6): 121–124. https://doi.org/10.1111/j.0954-6820.1981.tb11563.x.

  8. Lindop GB, Fleming S. Renin in renal cellcarcinoma--an immunocytochemical studyusing an antibody to pure human renin. Journalof Clinical Pathology. 1984;37(1): 27–31. https://doi.org/10.1136/jcp.37.1.27.

  9. Kirchner FK, Braren V, Smith C, Wilson JP,Foster JH, Hollifield JW, et al. Renal CarcinomaDiscovered Incidentally by ArteriographyDuring Evaluation for Hypertension. Journalof Urology. 1976;115(6): 643–645. https://doi.org/10.1016/s0022-5347(17)59319-2.

  10. Maldonado JE, Sheps SG, Bernatz PE, DeWeerdJH, Harrison EG. Renal arteriovenous fistula.The American Journal of Medicine. 1964;37(4):499–513. https://doi.org/10.1016/0002-9343(64)90064-6.

  11. Sufrin G, Mirand EA, Moore RH, Chu TM,Murphy GP. Hormones in renal cancer.Transactions of the American Association ofGenito-Urinary Surgeons. 1976;68: 115–120.

  12. Kranidiotis GP, Voidonikola PT, DimopoulosMK, Anastasiou-Nana MI. Stauffer’s syndromeas a prominent manifestation of renal cancer:a case report. Cases Journal. 2009;2(1): 49.https://doi.org/10.1186/1757-1626-2-49.

  13. Tanous B, Alsaud A, Mahmoud KE, Yassin MA.A Rare Presentation of Stauffer’s SyndromeAssociated with Renal Cell Carcinoma. CaseReports in Oncology. 2020;13(2): 742–746.https://doi.org/10.1159/000508039.

  14. Tashjian AH. Prostaglandins, Hypercalcemiaand Cancer. New England Journal of Medicine.1975;293(25): 1317–1318. https://doi.org/10.1056/nejm197512182932511.

  15. Blay JY, Rossi JF, Wijdenes J, Menetrier-Caux C, Schemann S, Négrier S, et al. Role ofinterleukin-6 in the paraneoplastic inflammatorysyndrome associated with renal-cell carcinoma.International Journal of Cancer. 1997;72(3):424–430. https://doi.org/10.1002/(sici)1097-0215(19970729)72:3<424::aid-ijc9>3.0.co;2-r.

  16. Ikuerowo S, Ojewuyi O, Omisanjo O,Abolarinwa A, Bioku M, Doherty A.Paraneoplastic syndromes and oncologicaloutcomes in renal cancer. Nigerian Journal ofClinical Practice. 2019;22(9): 1271. https://doi.org/10.4103/njcp.njcp_35_19.

  17. Fichman M, Bethune J. Effects of neoplasms onrenal electrolyte function. Annals of the New YorkAcademy of Sciences. 1974;230(1): 448–472.https://doi.org/10.1111/j.1749-6632.1974.tb14479.x.

  18. Strum WB. Remote recurrence of renal cellcarcinoma. Urology. 1984;23(1): 68–70. https://doi.org/10.1016/0090-4295(84)90181-x.




2020     |     www.medigraphic.com